A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia

2006 ◽  
Vol 21 (4) ◽  
pp. 421-427 ◽  
Author(s):  
Bong-Ju Lee ◽  
Jung-Goo Lee ◽  
Young-Hoon Kim
Keyword(s):  
Cognitive Impairments ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Double Blind ◽  
Double Blind Placebo

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial

2010 ◽  
Vol 179 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Iulian Iancu ◽  
Eleonora Tschernihovsky ◽  
Ehud Bodner ◽  
Anna Sapir Piconne ◽  
Katherine Lowengrub
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Double Blind ◽  
Double Blind Placebo

Oxypertine in Tardive Dyskinesia: An 8-week Controlled Study

1984 ◽  
Vol 144 (1) ◽  
pp. 48-52 ◽  
Author(s):  
S. D. Soni ◽  
H. L. Freeman ◽  
E. M. Hussein
Keyword(s):  
Tardive Dyskinesia ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

SummaryIn a double-blind placebo controlled trial of oxypertine in the treatment of tardive dyskinesia, 33 patients with chronic schizophrenia received either oxypertine or placebo. At the end of eight weeks, the results showed that oxypertine was superior to placebo at a statistically significant level.

Sign in / Sign up

Export Citation Format

Share Document